<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499833</url>
  </required_header>
  <id_info>
    <org_study_id>CHULC.CI.HCC.2020</org_study_id>
    <nct_id>NCT04499833</nct_id>
  </id_info>
  <brief_title>HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma</brief_title>
  <acronym>HepatoPredict</acronym>
  <official_title>Evaluation of the HepatoPredict Prognostic Tool in the Decision of Liver Transplant in Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Hospitalar de Lisboa Central</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ophiomics - Precision Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Hospitalar de Lisboa Central</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver transplant is the most effective treatment for hepatocellular carcinoma (HCC) in&#xD;
      cirrhosis. Due to organs shortage, the proper selection of patients is imperative. Prevailing&#xD;
      clinical morphological models used in most centres (Milan Criteria), can exclude potential&#xD;
      candidates and include patients with aggressive biological behaviour. To more accurately&#xD;
      select candidates for liver transplant, the inclusion of criteria that could predict the&#xD;
      behaviour and aggressiveness of tumours, such as molecular markers, might be useful.&#xD;
&#xD;
      The investigators propose the use of a new algorithm (HepatoPredict Prognostic Tool), that&#xD;
      combine clinical and molecular criteria that address the biology of tumours, in a single&#xD;
      centre prospective, intervention study. Data from the &quot;HepatoPredict genomic signature&quot; are&#xD;
      added to the clinical and imagiology algorithm. Based on this tool, patients outside the&#xD;
      usual eligibility criteria for liver transplant will be proposed for this treatment. These&#xD;
      patients will be transplanted with marginal livers or with livers from patients with Familial&#xD;
      Amyloid Polyneuropathy, not competing with patients on the waiting list. Patients will be&#xD;
      followed up to 60 months after transplant, to assess survival and HCC recurrence with&#xD;
      biannual imagiology screening. Survival and disease-free-survival rates will be compared with&#xD;
      those obtained by the usual management of patients included and excluded by Milan Criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver transplant is the most effective treatment for hepatocellular carcinoma (HCC) in&#xD;
      cirrhosis. Due to organs shortage, the proper selection of patients is imperative. Prevailing&#xD;
      clinical morphological models used in most centres (Milan Criteria), can exclude potential&#xD;
      candidates and include patients with aggressive biological behaviour. To more accurately&#xD;
      select candidates for liver transplant, the inclusion of criteria that could predict the&#xD;
      behaviour and aggressiveness of tumours, such as molecular markers, might be useful. The&#xD;
      investigators propose the use of a new algorithm (HepatoPredict Prognostic Tool, Ophiomics),&#xD;
      combining morphologic information, clinical and molecular criteria, in a prospective,&#xD;
      intervention, single centre study.&#xD;
&#xD;
      Patients aged 18 to 70 years, with HCC in cirrhosis, not eligible for liver transplant under&#xD;
      the &quot;Milan Criteria&quot;, whom had the following morphologic characteristics: total tumour volume&#xD;
      below 500 cm3, total number of tumour lesions below 10 and maximum individual tumour diameter&#xD;
      below 10 cm, will be proposed for the &quot;HepatoPredict genomic signature&quot; analysis (Ophiomics),&#xD;
      obtained from DNA of tumor samples. Those considered candidates by the algorithm are to be&#xD;
      proposed for transplant with marginal livers or with livers from patients with Familial&#xD;
      Amyloid Polyneuropathy.&#xD;
&#xD;
      Patients will be followed up to 60 months after transplant, to assess survival and HCC&#xD;
      recurrence with biannual imagiology screening by triphasic CT scan. Additionally, circulating&#xD;
      tumour DNA will be assessed previously to the transplant and biannually for up to 60 months.&#xD;
      Survival and disease-free-survival rates will be compared with those obtained with the usual&#xD;
      management of patients included and excluded by Milan Criteria, both in the same referral&#xD;
      transplant center and in the published literature.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective evaluation of patients with hepatocellular carcinoma in cirrhotic liver, outside the &quot;Milan Criteria&quot; for liver transplant, that comply with the morphologic criteria stablished for the proposed HepatoPredict Tool: (1) Total tumour volume below 500 cm3; (2) Total number of tumour lesions below 10; and (3) maximum individual tumour diameter below 10 cm. Those patients are proposed to be submitted to molecular study of the hepatocellular carcinoma and, if comply with the &quot;HepatoPredict genomic signature&quot;, liver transplantation will be proposed. Patients will be followed up for up to 5 years after transplantation for survival and survival-free-of-disease.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>from 6 months after liver transplant up to 60 months</time_frame>
    <description>death by any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hepatocellular carcinoma recurrence</measure>
    <time_frame>from 6 months after liver transplant up to 60 months</time_frame>
    <description>identification of hepatocellular carcinoma recurrence through biannual triphasic CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hepatocellular carcinoma recurrence through liquid biopsy</measure>
    <time_frame>from 6 months after liver transplant up to 60 months</time_frame>
    <description>early identification of hepatocellular carcinoma DNA through biannual serum samples (liquid biopsy)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatocellular Carcinoma, Scirrhous</condition>
  <condition>Recurrence Tumor</condition>
  <arm_group>
    <arm_group_label>liver transplant outside the &quot;Milan Criteria&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with hepatocellular carcinoma, outside the &quot;Milan Criteria&quot;, that complied with the proposed HepatoPredictTool, submitted to liver transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>liver transplant</intervention_name>
    <description>liver transplant</description>
    <arm_group_label>liver transplant outside the &quot;Milan Criteria&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hepatocellular carcinoma associated with cirrhosis&#xD;
&#xD;
          -  Ages between 18 and 70 years&#xD;
&#xD;
          -  Total tumour volume below 500 cm3&#xD;
&#xD;
          -  Total number of tumour lesions below 10&#xD;
&#xD;
          -  Maximum individual tumour diameter below 10 cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  eligible under the &quot;Milan Criteria&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo Pinto-Marques, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Hospitalar Universitário de Lisboa Central</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hugo Pinto-Marques, MD PhD</last_name>
    <phone>+351917302214</phone>
    <email>hugo.marques3@chlc.min-saude.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sílvia Gomes-da-Silva, MD</last_name>
    <phone>+351916876393</phone>
    <email>silvia.silva@chlc.min-saude.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Hepato-bilio-pancreático e de Transplantação do Hospital Curry Cabral</name>
      <address>
        <city>Lisboa</city>
        <zip>1069-166</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Hugo Pinto-Marques, MD PhD</last_name>
      <phone>+351917302214</phone>
      <email>hugo.marques3@chlc.min-saude.pt</email>
    </contact>
    <contact_backup>
      <last_name>Luis Pereira-de-Silva, MD PhD</last_name>
      <phone>+351213596402</phone>
      <phone_ext>51402</phone_ext>
      <email>centro.investigacao@chlc.min-saude.pt</email>
    </contact_backup>
    <investigator>
      <last_name>Sílvia Gomes-da-Silva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Pereira-Leal, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>July 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>liver transplant</keyword>
  <keyword>tumor recurrence</keyword>
  <keyword>biomarkers</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Adenocarcinoma, Scirrhous</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

